ECD Protein, Human (sf9, His-GST)

ECD proteins are multifunctional regulators of cellular dynamics that cooperate with TXNIP to stabilize and regulate p53/TP53 by inhibiting MDM2-mediated degradation. In addition to p53 stabilization, ECD is involved in complex transcriptional regulation, exhibits intrinsic transactivation activity, and may interact with EP300. ECD Protein, Human (sf9, His-GST) is the recombinant human-derived ECD protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

ECD, a versatile regulator in cellular dynamics, assumes a pivotal role in stabilizing and modulating the activity of the tumor suppressor p53/TP53. By inhibiting MDM2-mediated degradation of p53, ECD collaborates, potentially with TXNIP, to safeguard the integrity of this critical guardian of genomic stability. Beyond its role in p53 stabilization, ECD reveals a multifaceted nature, engaging in intricate transcriptional regulation. In vitro, it demonstrates intrinsic transactivation activity, further potentiated by its interaction with EP300, and may function as a transcriptional activator essential for the expression of glycolytic genes. Implicated in cell cycle progression, ECD is proposed to disrupt Rb-E2F binding, thereby activating E2F proteins, and this cell cycle-regulating function is intricately linked to its association with the RUVBL1-containing R2TP complex. Additionally, ECD's involvement in pre-mRNA splicing adds another layer to its regulatory repertoire. Interacting with a network of key proteins, including TP53, MDM2, TXNIP, PIH1D1, RUVBL1, RB1, RBL1, RBL2, and EP300, ECD emerges as a central player orchestrating diverse cellular processes.

Human

Sf9 insect cells

N-His;N-GST

O95905-1 (M1-N644)

11319  [NCBI]

Full Length of Isoform-1

MEETMKLATMEDTVEYCLFLIPDESRDSDKHKEILQKYIERIITRFAPMLVPYIWQNQPFNLKYKPGKGGVPAHMFGVTKFGDNIEDEWFIVYVIKQITKEFPELVARIEDNDGEFLLIEAADFLPKWLDPENSTNRVFFCHGELCIIPAPRKSGAESWLPTTPPTIPQALNIITAHSEKILASESIRAAVNRRIRGYPEKIQASLHRAHCFLPAGIVAVLKQRPRLVAAAVQAFYLRDPIDLRACRVFKTFLPETRIMTSVTFTKCLYAQLVQQRFVPDRRSGYRLPPPSDPQYRAHELGMKLAHGFEILCSKCSPHFSDCKKSLVTASPLWASFLESLKKNDYFKGLIEGSAQYRERLEMAENYFQLSVDWPESSLAMSPGEEILTLLQTIPFDIEDLKKEAANLPPEDDDQWLDLSPDQLDQLLQEAVGKKESESVSKEEKEQNYDLTEVSESMKAFISKVSTHKGAELPREPSEAPITFDADSFLNYFDKILGPRPNESDSDDLDDEDFECLDSDDDLDFETHEPGEEASLKGTLDNLKSYMAQMDQELAHTCISKSFTTRNQVEPVSQTTDNNSDEEDSGTGESVMAPVDVDLNLVSNILESYSSQAGLAGPASNLLQSMGVQLPDNTDHRPTSKPTKN

Approximately 88-108 kDa,based on SDS-PAGE under reducing conditions.

≥ 90%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.